Gilead U.S. Patient Assistance Programs

Gilead Patient Assistance Programs

Our U.S. patient assistance programs help make Gilead therapies accessible for uninsured individuals and those who need financial assistance.

Support Path™ assists eligible hepatitis C patients in the United States access Sovaldi® (sofosbuvir) or Harvoni® (ledipasvir/sofosbuvir). The program consists of an integrated offering of support services for patients and providers, among them:

A call center staffed with associates trained to help patients and their providers with insurance-related needs.

Education and support, including a 24/7 nursing support service line.

The Sovaldi and Harvoni Co-pay Coupon Programs, which provide co-pay assistance for eligible patients with private insurance who need assistance paying for their out-of-pocket medication costs. 

Most patients will pay no more than $5 per co-pay.

The Support Path Patient Assistance Program will provide Sovaldi and Harvoni at no charge for eligible patients with no other insurance options.

To learn more about Support Path for Sovaldi® and Harvoni®, please call 1-855-769-7284, Monday through Friday between 9:00 a.m. and 8:00 p.m. (Eastern Time).

Click here.....

Harvoni FDA APPROVED

U.S. Food and Drug Administration Approves Gilead’s Harvoni® (Ledipasvir/Sofosbuvir), the First Once-Daily Single Tablet Regimen for the Treatment of Genotype 1 Chronic Hepatitis C

Harvoni (ledipasvir and sofosbuvir)

Gilead has published both U.S. Prescribing Information and Patient Information, on their support website.

In addition check out HCV Advocates new factsheet for; Genotype 1:Treatment: Harvoni (Sofosbuvir & Ledipasvir), other factsheets include; Sovaldi: Genotype 1 Triple Therapy, Sovaldi: Genotype 2 & 3 and Sovaldi: Genotype 4 Triple Therapy

In case you missed it; HCV Newsetters: Everything you need to know about Gilead's Harvoni